#United States #biopharmaceuticals #El Segundo #Varda Space #Mikael Dolsten

Varda Space Welcomes Biopharma Expert Mikael Dolsten to Board

Varda Space Industries, a pioneer in orbital manufacturing, has recently announced the addition of prominent biopharma leader Mikael Dolsten to its board of directors. With a distinguished career that includes 16 years as the Chief Scientific Officer and President of Pfizer R&D, Dolsten brings a wealth of experience in pharmaceutical research and development to Varda. His tenure at Pfizer was marked by overseeing the approval of over 36 medicines and vaccines, in addition to advancing more than 150 drug candidates into clinical studies.

Dolsten’s appointment comes at a crucial time as Varda seeks to produce the first pharmaceutical created in space, intended for patients on Earth. During his career, Dolsten has established himself as a leader in translating cutting-edge scientific discoveries into effective therapeutic products. His expertise aligns perfectly with Varda’s vision of leveraging microgravity conditions to revolutionize drug formulation and manufacturing processes.

In a statement, Mikael Dolsten expressed his enthusiasm for the potential that space manufacturing holds for the future of medicine. He noted, "The history of medicine has always involved breakthroughs in manufacturing processes. Each advancement has expanded our capabilities, and Varda’s infrastructure is poised to make orbital manufacturing both reliable and repeatable. I'm excited to help harness this technology to create medications that can significantly impact patients' lives."

Varda's initiative to utilize microgravity for pharmaceutical development is particularly innovative. In a gravity-free environment, the behavior of active pharmaceutical ingredients can differ significantly compared to Earth, allowing for formulations that might otherwise be impossible. The company aims to normalize in-space pharmaceutical processing as a standard aspect of drug development, setting it apart from other players in the industry.

The Varda team, including co-founder and Board Chairman Delian Asparouhov, believes that space-made pharmaceuticals will become a cornerstone of modern medicine. Asparouhov stated, "We launched Varda with a clear mission that the first product manufactured in space would be a pharmaceutical. Mikael’s outstanding experience in drug discovery and development will be invaluable as we transition from validating technology to delivering space-produced medicines to the market."

Since commencing its mission in 2023, Varda has swiftly increased its frequency of flights, successfully completing multiple reentry missions. With ten more launches and reentries planned through 2027, Varda's W-series vehicles are designed to reach speeds of Mach 25 when returning from orbit. This capability not only positions Varda as a leader in orbital pharmaceutical production but also provides a reliable and cost-effective method for transporting materials and data back to Earth.

As the space industry continues to grow, Varda is committed to being at the forefront of making space manufacturing a reliable and routine process. They aim to collaborate with government and industry partners to further streamline the return of essential materials from space, paralleling the increasing launch rates across the sector.

Varda Space Industries is headquartered in El Segundo, California, and is building an infrastructure designed to support a flourishing orbital economy. Alongside its pharmaceutical processing initiatives, the company is also working on developing efficient hypersonic reentry capsules. With additional offices located in Washington, D.C., and Huntsville, Alabama, Varda is poised to make significant contributions to both pharmaceutical manufacturing and space exploration.

For more updates, follow Varda on social media platforms like X (@vardaspace), Instagram (@vardaspaceindustries), and LinkedIn.

By welcoming Mikael Dolsten to their board, Varda is not just bolstering its leadership with a seasoned biopharma veteran but is also signaling a bold step forward in its mission to redefine how we think about pharmaceutical development through innovative space-based manufacturing.